Literature DB >> 11309829

Leukodepletion for acute lymphocytic leukemia in a three-week-old infant.

S Woloskie1, H Armelagos, J M Meade, D Haas.   

Abstract

We report the smallest infant (4.5 kg) to receive leukapheresis as an immediate treatment for Infantile Acute Lymphocytic Leukemia. Leukodepletion helps prevent the risks of hyperviscosity and cerebrovascular and pulmonary leukostasis. In addition, it is a desirable precursor to chemotherapy to potentially reduce metabolic and renal complications associated with rapid cell lysis. Because of this infant's small size, she presented us with multiple concerns, including hypocalcemia from citrate anticoagulation, extracorporeal volume and fluid balance, inlet flow rates. and establishment of adequate interface. Our positive experience in performing this procedure suggests that cytapheresis is a feasible treatment even for very young infants.

Entities:  

Mesh:

Year:  2001        PMID: 11309829     DOI: 10.1002/jca.1006

Source DB:  PubMed          Journal:  J Clin Apher        ISSN: 0733-2459            Impact factor:   2.821


  4 in total

1.  Hyperleukocytosis in infant acute leukemia: a role for manual exchange transfusion for leukoreduction.

Authors:  Daniel V Runco; Cassandra D Josephson; Sunil S Raikar; Kelly C Goldsmith; Glen Lew; Melinda Pauly; Ross M Fasano
Journal:  Transfusion       Date:  2018-02-04       Impact factor: 3.157

2.  Leukapheresis protocol for nonhuman primates weighing less than 10 kg.

Authors:  Vimukthi Pathiraja; Abraham J Matar; Ashley Gusha; Christene A Huang; Raimon Duran-Struuck
Journal:  J Am Assoc Lab Anim Sci       Date:  2013-01       Impact factor: 1.232

3.  Leukapheresis in Pediatric Acute Leukemia with Hyperleukocytosis: A Single-Center Experience.

Authors:  Sandra Renee Jones; April Rahrig; Amanda J Saraf
Journal:  Children (Basel)       Date:  2022-04-02

4.  A high-throughput microfluidic device based on controlled incremental filtration to enable centrifugation-free, low extracorporeal volume leukapheresis.

Authors:  Dalia L Lezzar; Fong W Lam; Ravin Huerta; Anton Mukhamedshin; Madeleine Lu; Sergey S Shevkoplyas
Journal:  Sci Rep       Date:  2022-08-13       Impact factor: 4.996

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.